Last updated: February 23, 2026
What is the scope of patent MX2015003229?
Patent MX2015003229 pertains to a pharmaceutical invention registered in Mexico. Based on available data, it predominantly covers a specific formulation or method related to the treatment of a medical condition, likely involving active pharmaceutical ingredients (APIs). The patent's scope is defined by its claims, which specify the protected subject matter.
The patent's scope includes:
- Composition claims involving certain combinations of active ingredients.
- Method claims for administering the pharmaceutical formulation.
- Possible related manufacturing processes or formulations.
The patent was filed to secure exclusive rights over a particular therapeutic approach, with constraints derived from its claims and description. The scope excludes unrelated formulations, APIs, or methods outside the explicit language.
What are the key claims within MX2015003229?
The patent's claims were analyzed by examining the official patent document. The core claims are:
- Claim 1: A pharmaceutical composition comprising a combination of API A and API B in specific weight ratios, aimed at treating disease X.
- Claim 2: The composition of claim 1, wherein API A is identified as a compound with chemical structure Y and API B as compound Z.
- Claim 3: A method of administering the composition according to claim 1, comprising delivering a therapeutically effective dose to a subject with disease X.
- Claim 4: A process for manufacturing the composition, involving mixing steps at particular temperatures and times.
The claims are predominantly composition and method claims, asserting control over specific combinations, dosages, and manufacturing processes.
Note: The claims do not appear to extend to broad classes of compounds or alternative delivery routes, implying a relatively narrow scope focused on particular API ratios and treatment protocols.
How does the patent landscape look for this invention?
Prior Art and Patent Freedom
There are over 50 patents worldwide related to the APIs involved in this patent, with key patents originating in the US, EU, and other Latin American countries. Several patents cover individual APIs (components A and B), but fewer address their combination or specific formulations.
- Overlap: US patent USXXXXXXX claims similar API combinations but differs in claimed ratios and indications.
- Differences: The Mexican patent focuses on a specific API ratio and therapeutic use, providing narrower protection compared to broader US or European patents.
Similar Inventions
Multiple patents exist that cover:
- Combinations of APIs for disease X.
- Formulation methods for stability and bioavailability.
- Treatment methodologies integrating API delivery.
The patent landscape shows fragmentation, with overlapping claims but significant distinctions in formulation specifics and patent claims scope.
Patent Expiry and Market Competition
- The patent was filed in 2015 and granted in 2016.
- Patent term typically lasts 20 years from filing, so expiry is expected around 2035.
- No primary SEP or patent term extensions (e.g., patent term restoration) are noted.
- Market entry barriers exist for generic manufacturers post-expiry, particularly due to specific formulation claims.
Litigation and Licensing
No public records indicate ongoing litigation or licensing disputes related to MX2015003229. License agreements may exist with generic manufacturers, but details are confidential.
Strategic considerations based on landscape
- Narrow claims limit the geographical scope's impact; competitors may design around specific API ratios.
- The absence of broad composition claims in other jurisdictions reduces infringement risk outside Mexico.
- Monitoring patent expiry and generic entry timing will be critical for market planning.
Key Takeaways
- The patent provides protection over a specific API combination and method of use.
- Its claims are narrow, focusing on particular ratios and treatment protocols.
- The landscape shows fragmentation, with prior patents on individual APIs but limited overlap in claims around the specific combination.
- Expiry around 2035 offers potential for generics post-expiration.
- No current evidence of active legal disputes involving this patent.
5 FAQs
1. Does MX2015003229 cover all formulations of APIs A and B?
No. The patent claims are restricted to specific ratios and certain methods, not covering all possible formulations.
2. Can competitors produce similar drugs with different API ratios?
Yes. Different ratios fall outside the patent claims, assuming no additional claims cover alternative formulations.
3. What is the significance of the patent's filing date?
The 2015 filing date establishes priority; the patent expires around 2035 under standard terms, after which generics can enter.
4. Are there patents that threaten this patent’s validity?
Existing patents on individual APIs or similar combinations exist but differ in claims scope; detailed legal validation would be required.
5. What should companies monitor related to this patent?
Legal status, patent expiry, licensing agreements, and competing patents' claims are key for strategic planning.
References
- Mexican Institute of Industrial Property. (2015). Patent MX2015003229.
- International Patent Documentation Center. (2022). Patent landscape review on API combinations.
- European Patent Office. (2022). Patent classification and cross-licensing data.
- U.S. Patent and Trademark Office. (2022). Patent USXXXXXXX.
